Valuation: Rocket Pharmaceuticals, Inc.

Market Cap 284M 251M 237M 215M 404M 27.28B 408M 2.85B 1.1B 13.93B 1.07B 1.04B 44.83B P/E 2026 *
-9.36x
P/E 2027 * -1.86x
Enterprise Value -36.28M -32.02M -30.3M -27.47M -51.51M -3.48B -52.02M -363M -140M -1.78B -136M -133M -5.72B EV / Sales 2026 *
-32.8x
EV / Sales 2027 * -4.52x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-0.77%
1 week-22.69%
Current month-30.38%
1 month-32.90%
3 months-23.15%
6 months-31.30%
Current year-26.21%
1 week 2.51
Extreme 2.51
3.02
1 month 2.51
Extreme 2.51
3.96
Current year 2.51
Extreme 2.51
5.45
1 year 2.51
Extreme 2.51
5.45
3 years 2.19
Extreme 2.19
32.52
5 years 2.19
Extreme 2.19
36.87
10 years 2.19
Extreme 2.19
67.48
Manager TitleAgeSince
Chief Executive Officer 51 2018-01-03
Director of Finance/CFO 49 2025-09-07
Chief Tech/Sci/R&D Officer 59 2025-08-31
Director TitleAgeSince
Director/Board Member 51 2018-01-03
Chairman 49 2017-12-31
Director/Board Member 65 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Sell

Chief Financial Officer

-75,364 0.0687%
8/18/26 Sell

Chief Executive Officer

-2,293 0.0021%
8/18/26 Sell

Chief Financial Officer

-631 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-22.69%-21.04%-87.36% 284M
-0.70%-4.28%+52.62%+86.42% 71.53B
+0.57%+2.08%+38.24%+82.70% 60.12B
+4.95%+6.34%+37.02%+26.32% 27.98B
-1.73%-4.30%-18.37%+357.94% 25.25B
-0.51%-2.28%+0.48%-9.27% 24.76B
+1.17%+1.92%+21.19%-4.42% 20.99B
+3.46%+3.02%+158.90%+337.81% 15.54B
+0.48%+0.86%+44.56%+168.42% 14.53B
+2.96%+0.62%-5.45%+518.32% 14.41B
Average +0.97%-2.98%+30.82%+147.69% 27.54B
Weighted average by Cap. +0.69%-1.54%+36.76%+129.80%

Financials

2026 *2027 *
Net sales 1.11M 977K 925K 838K 1.57M 106M 1.59M 11.09M 4.27M 54.25M 4.16M 4.07M 175M 11.25M 9.92M 9.39M 8.52M 15.96M 1.08B 16.12M 113M 43.41M 551M 42.23M 41.31M 1.77B
Net income -17.76M -15.67M -14.83M -13.45M -25.21M -1.7B -25.46M -178M -68.56M -870M -66.69M -65.24M -2.8B -182M -161M -152M -138M -259M -17.51B -262M -1.83B -704M -8.94B -685M -670M -28.77B
Net Debt -321M -283M -268M -243M -455M -30.76B -460M -3.21B -1.24B -15.71B -1.2B -1.18B -50.55B -335M -296M -280M -254M -476M -32.16B -481M -3.36B -1.29B -16.42B -1.26B -1.23B -52.85B
Logo Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Employees
202
Date Price Change Volume
26-09-29 US$2.590 -0.77% 1,154,460
26-09-28 US$2.610 +0.58% 2,079,367
26-09-25 US$2.595 -3.53% 2,630,492
26-09-24 US$2.690 -10.93% 4,384,224
26-09-23 US$3.020 -9.85% 2,778,234
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2.590USD
Average target price
8.854USD
Spread / Average Target
+241.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCKT Stock